Emory University – Chronic myeloid leukemia

Access Program Information

<p><strong>Allogeneic hematopoietic stem cell transplantation (HSCT)</strong> is an established form of treatment for hematological abnormalities. Poor donor engraftment may result in poor graft function. A second infusion of unselected donor hematopoietic stem cells (HSC) can result in improvement, but can potentially increase the incidence of graft versus host disease. CD34+ selected stem cells depleted of T-cells is an attractive alternative for treatment of poor graft function as it may be associated with less Graft versus Host Disease (GVHD) and enhanced count recovery. The investigators are using the Miltenyi CliniMACS device and CD34 cell selection reagents for the preparation of allogeneic hematopoietic progenitor cell (HPC) transplants for patients who have had prior stem cell transplants and require a stem cell “boost” from the original donor.</p>